Opioid addiction treatment is more widely available, but only for adults

June 04, 2020

Prescriptions for an FDA-approved treatment for opioid addiction have increased over the past decade in all age groups except the youngest (age 15-24), a new analysis of prescription data by researchers at Columbia University Irving Medical Center has found.

Expanded access to the treatment among adults is being driven primarily by an increase in prescriptions from primary care providers, rather than psychiatrists or other specialists, the researchers found, while decreased access among young adults and teens mostly stems from a decrease in prescriptions from psychiatrists and addiction medicine specialists.

To prescribe buprenorphine, physicians must complete a training course and obtain a waiver from the U.S. Drug Enforcement Administration. Amendments to federal legislation in 2006 and 2016 extended eligibility for the waivers and waiver limits.

"More than any other provider group, primary care providers offer greater potential for expanding access to buprenorphine treatment because there is such a large number of them who either do not have waivers or are not near their waiver limits," says the study's leader Mark Olfson, MD, MPH, the Elizabeth K. Dollard Professor of Psychiatry, Medicine, and Law at Columbia University Vagelos College of Physicians and Surgeons.

Between 2000 and 2018, buprenorphine treatment initiated by prescriptions from primary care providers more than doubled, from 12.9 per 10,000 people to 27.4 per 10,000 people. Among psychiatrists and addiction medicine specialists, buprenorphine prescriptions increased from 8.7 to 12 per 10,000 people.

But when data from different age groups were examined, prescriptions for adolescents and young adults (age 15 to 24) actually dropped, from 20.4 per 10,000 people to 14 per 10,000 people.

"This is a worrisome trend, given the high rate of opioid-related overdose deaths among young people," says Olfson. "We hope that awareness of this trend will encourage expansion of substance use treatment programs that accept adolescents and cater to young adults."

The study also found that while there was a slight increase in the percentage of patients continuing the medication for at least 180 days -- an important benchmark in addiction treatment -- less than one-third of patients achieved this target.

"In response to the COVID-19 pandemic, clinicians may be finding new ways to continue their patients' treatment with buprenorphine, as providers relax requirements such as direct observation of treatment induction or urine drug screening," says Olfson. "Such changes will hopefully increase access to treatment without adding risks. It will be important to monitor community buprenorphine treatment patterns through this critical period."
The paper, titled "Buprenorphine Treatment by Primary Care Providers, Psychiatrists, Addiction Specialists, and Others," was published June 1, 2020, in Health Affairs.

The other authors are Victoria (Shu) Zhang (Yale University, New Haven, CT), Michael Schoenbaum (National Institute of Mental Health, Bethesda, MD), and Marissa King (Yale).

The study was supported by a grant from the National Institute on Drug Abuse (R01DA044981). The authors report no financial or other conflicts of interest.

Columbia University Irving Medical Center

Related Buprenorphine Articles from Brightsurf:

Treating opioid addiction in primary care helps patients and cash-strapped medical practices
Buprenorphine-based treatment for opioid addiction is in short supply in many areas of the United States.

Patients' access to opioid treatment cumbersome
The 'secret shopper' study used trained actors attempting to get into treatment with an addiction provider in 10 US states.

Opioid addiction treatment is more widely available, but only for adults
Primary care providers have expanded access to buprenorphine for adults, but use of the opioid addiction treatment has decreased among the youngest patients, find researchers at Columbia University.

Emergency departments slow to adopt proven opioid use disorder therapy
A new study by Yale researchers looking at nearly 400 clinicians at four urban academic emergency departments found that, despite scientific evidence supporting the benefits of buprenorphine for opioid use disorder, just 21% of emergency department clinicians indicated readiness to offer it to patients in need.

Continuity of buprenorphine treatment linked to significantly lower prescription opioid use and over
A study at Columbia University Mailman School of Public Health found that long-term buprenorphine treatment is associated with improvements in health care outcomes.

Financial incentives boost doctor training in opioid treatment medication
Offering $750 to emergency medicine physicians exponentially increased those trained to prescribe buprenorphine.

Nearly one-third of primary care providers do not view medication treatment for opioid use disorder as effective
A new survey of US primary care physicians from researchers at Johns Hopkins Bloomberg School of Public Health found that nearly one-third, 32.9 percent, do not think treating opioid use disorder with medication is any more effective than treatment without medication.

Study reveals pharmacy-level barriers to treatment for opioid use disorder in Appalachian Kentucky
A new study led by University of Kentucky researcher April Young and Emory University researcher Hannah Cooper shows that a number of pharmacies in the Appalachian region of Kentucky are limiting the dispensing of buprenorphine, a medication used to treat opioid use disorder (OUD).

Less addictive form of buprenorphine may help curb cocaine relapse
New research performed in mice suggests that chemical modifications to buprenorphine can improve its effectiveness to treat cocaine addiction while minimizing abuse potential.

Residencies must train residents to treat substance use disorder among pregnant women
Early-career family physicians who both provide maternity care and prescribe buprenorphine -- a medication used to treat opioid use disorder -- primarily completed their training in a small number of residency programs.

Read More: Buprenorphine News and Buprenorphine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.